NeuroVive sums up 2019 and wishes a Merry Christmas

Open the attached PDF to read the full newsletter.

Newsletter December 2019

In this issue:

  • CEO Erik Kinnman sums up 2019
  • Interview with Dr. Amel Karaa
  • The Nobel Prize and mitochondria

Read more about us at
Follow us on LinkedIn
View our videos, interviews and presentations by subscribing to our YouTube channel

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).





2019 was a good year for NeuroVive with significant advances in our projects for primary mitochondrial diseases. 2020 has the potential to be an even stronger year!
Erik Kinnman, CEO